164 related articles for article (PubMed ID: 24384233)
1. Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.
Hemmerle T; Hess C; Venetz D; Neri D
J Biotechnol; 2014 Feb; 172():73-6. PubMed ID: 24384233
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
3. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
4. Superior serum half life of albumin tagged TNF ligands.
Müller N; Schneider B; Pfizenmaier K; Wajant H
Biochem Biophys Res Commun; 2010 Jun; 396(4):793-9. PubMed ID: 20447380
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.
Stringhini M; Mock J; Fontana V; Murer P; Neri D
MAbs; 2021; 13(1):1868066. PubMed ID: 33404287
[TBL] [Abstract][Full Text] [Related]
7. Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.
Doll F; Schwager K; Hemmerle T; Neri D
Arthritis Res Ther; 2013 Sep; 15(5):R138. PubMed ID: 24289726
[TBL] [Abstract][Full Text] [Related]
8. Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines.
Phillips TA; Ni J; Hunt JS
Placenta; 2001; 22(8-9):663-72. PubMed ID: 11597186
[TBL] [Abstract][Full Text] [Related]
9. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.
Ziffels B; Grötsch A; Al-Bayati L; Neri D
J Biotechnol; 2019 Jan; 290():53-58. PubMed ID: 30579890
[TBL] [Abstract][Full Text] [Related]
11. Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.
Schmid AS; Tintor D; Neri D
J Biotechnol; 2018 Apr; 271():29-36. PubMed ID: 29438784
[TBL] [Abstract][Full Text] [Related]
12. Generation of rabbit antibodies against death ligands by cDNA immunization.
Diestre C; Martínez-Lorenzo MJ; Bosque A; Naval J; Larrad L; Anel A
J Immunol Methods; 2006 Dec; 317(1-2):12-20. PubMed ID: 17045605
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.
Hess C; Neri D
Exp Biol Med (Maywood); 2014 Jul; 239(7):842-852. PubMed ID: 24872435
[TBL] [Abstract][Full Text] [Related]
14. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
Hemmerle T; Neri D
Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications.
Steiner M; Gutbrodt K; Krall N; Neri D
Bioconjug Chem; 2013 Feb; 24(2):234-41. PubMed ID: 23350721
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
17. TRAIL but not FasL and TNFα, regulates IL-33 expression in murine hepatocytes during acute hepatitis.
Arshad MI; Piquet-Pellorce C; L'Helgoualc'h A; Rauch M; Patrat-Delon S; Ezan F; Lucas-Clerc C; Nabti S; Lehuen A; Cubero FJ; Girard JP; Trautwein C; Samson M
Hepatology; 2012 Dec; 56(6):2353-62. PubMed ID: 22961755
[TBL] [Abstract][Full Text] [Related]
18. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
19. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
20. A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.
Hemmerle T; Wulhfard S; Neri D
Protein Eng Des Sel; 2012 Dec; 25(12):851-4. PubMed ID: 22972762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
